For patients without established atherosclerotic CV disease (ASCVD) or chronic kidney disease (CKD) and for whom there is a compelling need to minimize weight gain or promote weight loss, the American Diabetes Association (ADA) and European Association for the Study of Diabetes (EASD) guidelines recommend GLP-1RA and sodium-glucose co-transporter-2 inhibitor (SGLT2i) drugs as the preferred second-line treatment option for patients with inadequate glycemic control despite use of metformin [1, 9]
The receipt took a long time to load and initially showed an error
Combining semaglutides powerful hunger-dampening effects with topiramates ability to quiet the food noise in the brain can be a highly effective strategy for those who have struggled with treatment resistance
The majority of these events were mild to moderate in severity and transient, occurring during dose escalation and resolving over days to weeks as participants adapted
If a patient stops the medication, diabetes will relapse (if it was controlled, not cured) and weight will likely be regained, as evidenced by trials where cessation led to weight regain trends
However, relapse rates remain high, and many currently approved medications exhibit limitations in efficacy and patient adherence